How India Exports Salmeterol to the World

In the United States, salmeterol is approved for the treatment of asthma and COPD. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for salmeterol-containing products, indicating a competitive generic market. Notably, the original New Drug Application (NDA) for Serevent (salmeterol xinafoate inhalation) Diskus was approved on September 15, 1998. The regulatory pathway for salmeterol involves demonstrating bioequivalence to the reference listed drug, adherence to Good Manufacturing Practices (GMP), and compliance with labeling requirements. Given the presence of 148 active Indian exporters, it is imperative for these entities to ensure compliance with FDA regulations to maintain market access.

In the European Union, salmeterol is authorized for use in asthma and COPD management. The European Medicines Agency (EMA) has granted marketing authorizations for various salmeterol-containing products. For instance, Seffalair Spiromax received EU-wide approval on March 26, 2021. (ema.europa.eu) However, some products, such as BroPair Spiromax, had their marketing authorizations withdrawn on May 23, 2025, at the request of the marketing authorization holder for commercial reasons. (ema.europa.eu) Manufacturers exporting to the EU and UK must comply with EMA and Medicines and Healthcare products Regulatory Agency (MHRA) regulations, including obtaining marketing authorizations and adhering to EU GMP standards.

Salmeterol is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in global health. The WHO Prequalification Programme ensures that medicines meet global standards of quality, safety, and efficacy. Additionally, salmeterol formulations are standardized in various pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), providing quality benchmarks for manufacturers and regulators.

In India, salmeterol is classified under Schedule H of the Drugs and Cosmetics Act, requiring a prescription for dispensing. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, specific ceiling prices for salmeterol are subject to periodic revisions. Exporters must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for the export of pharmaceutical products, ensuring compliance with national regulations.

The primary patents for salmeterol have expired, leading to increased generic competition globally. This has facilitated the entry of multiple manufacturers into the market, contributing to the significant export activity from India.

In June 2025, the EMA updated the product information for Seffalair Spiromax, reflecting new safety data. (ema.europa.eu) In December 2025, the EMA revised the product information for Bemrist Breezhaler, another inhalation product, to include updated safety and efficacy data. (ema.europa.eu) These developments highlight the dynamic nature of the regulatory landscape for inhalation therapies in the EU.

In summary, the regulatory landscape for salmeterol is characterized by established approvals in major markets, adherence to international quality standards, and a competitive environment due to patent expirations. Indian exporters must navigate these regulations diligently to maintain and expand their global market presence.

India's pharmaceutical industry, including the production of Salmeterol, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 60–70% of these essential components are sourced from China, underscoring a significant dependency. This reliance exposes the supply chain to potential disruptions stemming from geopolitical tensions, trade restrictions, or production issues within China.

In recent years, the Indian government has recognized this vulnerability and initiated measures to bolster domestic API and KSM production. The Production Linked Incentive (PLI) scheme, launched in 2020, aims to reduce dependence on imports by incentivizing local manufacturing. However, as of March 2026, the scheme's impact on decreasing reliance on Chinese imports remains limited, with the majority of raw materials still being sourced externally.

Our proprietary trade data from 2022 to 2026 reveals a high supplier concentration in Salmeterol exports from India. The top five exporters account for 92.5% of the total export value, with CIPLA LIMITED alone contributing 76.5% ($55.7 million). This significant concentration poses a single-source risk; any operational or regulatory issues affecting CIPLA LIMITED could substantially disrupt the global supply of Salmeterol.

While the PLI scheme aims to diversify and strengthen the pharmaceutical manufacturing base, its current influence on reducing supplier concentration in Salmeterol exports appears minimal. The market remains heavily reliant on a few key players, indicating a need for further strategic initiatives to mitigate single-source risks.

The ongoing conflict in the Middle East, particularly the closure of the Strait of Hormuz since February 28, 2026, has severely disrupted global shipping routes. This strait is a critical chokepoint for maritime trade, and its closure has led to significant delays and increased shipping costs. Major shipping companies have suspended transits through the region, opting for longer routes around the Cape of Good Hope, adding 10–14 days and up to $1 million in additional costs per trip.

While these disruptions primarily affect energy and bulk commodities, the ripple effects extend to containerized goods, including pharmaceuticals. Increased transit times and costs can lead to supply chain delays, impacting the timely delivery of Salmeterol to international markets. As of March 2026, there have been no specific shortage alerts for Salmeterol issued by the FDA or EMA. However, the potential for future shortages remains if the geopolitical situation persists or escalates.

• Diversify API and KSM Sources: Encourage and invest in the development of alternative sources for APIs and KSMs, both domestically and from other countries, to reduce dependency on Chinese imports.

• Expand Supplier Base: Promote the growth of additional manufacturers for Salmeterol to decrease reliance on a limited number of exporters, thereby mitigating single-source risks.

• Enhance Supply Chain Visibility: Implement advanced tracking and monitoring systems to gain real-time insights into the supply chain, allowing for proactive responses to potential disruptions.

• Develop Contingency Plans: Establish comprehensive contingency strategies, including alternative shipping routes and logistics partnerships, to navigate around geopolitical hotspots and ensure continuity of supply.

• Engage in Policy Advocacy: Collaborate with industry associations and government bodies to advocate for policies that support supply chain resilience, such as incentives for domestic production and infrastructure improvements.

RISK_LEVEL: HIGH